Sort
82,697 grants matching “vaccine development”
BSL3 Practices Core
$813,456Jay Rappaport · Tulane University Of Louisiana · UC7 · FY2023 · AI
Evaluating human T cells specific for Mycobacterium tuberculosis antigens that are processed and presented by infected macrophages
$813,450Stephen Matthew Carpenter · Case Western Reserve University · R01 · FY2025 · AI
Harnessing Abs specific for immunogenic and conserved Env epitopes to protect against HIV
$813,378Catarina E Hioe · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · AI
Harnessing Abs specific for immunogenic and conserved Env epitopes to protect against HIV
$813,378Catarina E Hioe · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · AI
Harnessing Abs specific for immunogenic and conserved Env epitopes to protect against HIV
$813,378Catarina E Hioe · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · AI
Novel Targets for Vaccine Therapy
$813,239Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2015 · CA
Optimization of Lead BKIs for Cryptosporidiosis Therapy
$813,238Wesley C Van Voorhis · University Of Washington · R01 · FY2025 · AI
mRNA-LNP vaccines targeting multiple stages and multiple species of human malaria parasite
$813,160Nirbhay Kumar · George Washington University · R01 · FY2025 · AI
TASK A105: SMALL ANIMAL MODELS FOR BIODEFENSE VIRUSES
$813,138John Morrey · Utah State University · N01 · FY2017 · AI
THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE
$813,113Alessandro Sette · La Jolla Institute For Immunology · U24 · FY2024 · CA
Cytokines in AIDS and Cancer
$813,040George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection
$813,038Ada S Cowan · Metallopharm, Llc · R44 · FY2012 · AA
COBRE for Perinatal Biology
$812,903Sunil K Shaw · Women And Infants Hospital-Rhode Island · P30 · FY2017 · GM
Host factors, inflammation, and HIV associated TB
$812,899Anne Goldfeld · Boston Children'S Hospital · R56 · FY2015 · HL
Zika virus nonstructural protein 5 inhibition of interferon signaling
$812,848Matthew J Evans · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · AI
Generation of highly differentiated NK cells to act in synergy with broadly neutralizing antibodies to reduce the SIV reservoir and establish viral control in absence of ART
$812,810Mirko Paiardini · Emory University · R56 · FY2023 · AI
Development and In Vivo Characterization of Safety-Enhanced RhCMV/SIV Vectors
$812,795Louis J. Picker · Oregon Health & Science University · R01 · FY2012 · AI
Long term adverse health outcomes for women and children following SARS-CoV-2 infection during pregnancy
$812,782Monique Marie Hedderson · Kaiser Foundation Research Institute · R01 · FY2025 · AI
The function of atypical B cells in the immune response against malaria
$812,704Evelien Margaretha Bunnik · University Of Texas Hlth Science Center · R56 · FY2025 · AI
Novel DNA-Launched Attenuated Vaccine for VEE Virus SBIR Phase II
$812,615Peter M. Pushko · Medigen, Inc. · R44 · FY2017 · AI
Systemic and gastrointestinal targeted CDPK1 inhibitors for cryptosporidiosis
$812,603Gregory D Cuny · University Of Houston · R01 · FY2025 · AI
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
$812,575Mihai Luchian Azoitei · Duke University · R01 · FY2021 · AI
Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes
$812,498Harvey Michael Friedman · University Of Pennsylvania · R01 · FY2024 · AI
Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes
$812,498Harvey Michael Friedman · University Of Pennsylvania · R01 · FY2023 · AI
Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes
$812,498Harvey Michael Friedman · University Of Pennsylvania · R01 · FY2025 · AI